Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).~* Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.~* Karnofsky Performance Status ≥ 80~* Informed consent~* Adequate bone marrow function, liver and renal function (neutrophils \> 1.5 x 10\^9/l; thrombocytes \> 100 x 10\^9/l; hemoglobin \> 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal \[ULN\] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT \< 5 x UNL; serum creatinine ≤ 1.5 x UNL)~* Age ≥ 18 years~Exclusion Criteria:~* Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence~* Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)~* Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy~* Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry~* Concurrent systemic immune therapy, chemotherapy, or hormone therapy~* Investigational agents or participation in clinical trials within 30 days before start of the treatment in study~* Clinically relevant coronary disease or myocardial infarction within 12 months before study entry~* Peripheral neuropathy \> CTC grade I~* Inflammatory bowel disease~* Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)~* History of severe psychiatric illness~* Drug or alcohol abuse~* Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Cetuximab and FOLFIRI
- 2 (Type: ACTIVE_COMPARATOR): Cetuximab and FOLFOX

Based on this trial design, predict the completion outcome and termination type (if applicable).